Unfortunately, in clinical studies, the administration of these ABCB1 inhibitors, along with anticancer drugs, showed poor results, with no benefits on the OS and DFS in patients bearing different types of cancers, including breast cancer [78]. Here, ABCB1 is linked to breast cancer.